Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2

Safwat, Akmal; Aggerholm, Ninna; Roitt, Ivan M.; Overgaard, Jens; Hokland, Marianne

doi:10.1016/j.ejca.2004.01.037

Cited by 15 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Her excellent response to intralesional IL-2 may have been augmented by the prior radiation therapy she received to the tumor, which has been reported to synergize with IL-2 therapy. 9 Patient 2 had a complete response within 3 months with resolution of all 3 tumors located on his scalp. He is currently living without recurrence.…”

Section: J Am Acad Dermatolmentioning

confidence: 96%

100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series

Shi

Tran

Patel

et al. 2015

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

show abstract

Section: J Am Acad Dermatolmentioning

confidence: 96%

100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series

Shi

Tran

Patel

et al. 2015

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

show abstract

“…A follow-up study demonstrated that delaying the start of treatment by 3 days allowed for melanoma disease burden to double. With the increase in disease burden, the efficacy of low dose TBI and IL-2 was abrogated unless the dose of IL-2 was doubled (52). In a later publication, the authors noted that CD4+ CD25+ suppressor cells also increased with tumor melanoma disease burden (53).…”

Section: Introductionmentioning

confidence: 99%

Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes

Barker

Postow

2014

International Journal of Radiation Oncology*Biology*Physics

139

View full text Add to dashboard Cite

Radiotherapy has long played a role in the management of melanoma. Recent advances have also demonstrated the efficacy of immunotherapy in the treatment of melanoma. Preclinical data suggest a biologic interaction between radiotherapy and immunotherapy. Several clinical studies corroborate these findings. This review will summarize the outcomes of studies reporting on patients with melanoma treated with a combination of radiotherapy and immunotherapy. Vaccine therapies often use irradiated melanoma cells, and may be enhanced by radiotherapy. The cytokines interferon-alpha and interleukin-2 have been combined with radiotherapy in several small studies, with some evidence suggesting increased toxicity and/or efficacy. Ipilimumab, a monoclonal antibody which blocks cytotoxic T-lymphocyte antigen-4, has been combined with radiotherapy in several notable case studies and series. Finally, pilot studies of adoptive cell transfer have suggested radiotherapy may improve the efficacy of treatment. The review will demonstrate that the combination of radiotherapy and immunotherapy has been reported in several notable case studies, series and clinical trials. These clinical results suggest interaction and the need for further study.

show abstract

“…Four patients showed a significant shrinkage of the tumor at the irradiated site and 2 patients showed an abscopal effect outside the irradiation field (54). Low-dose total body irradiation exhibited a synergistic immune-mediated anti-tumor effect when used in combination with IL-2 in a murine metastatic malignant melanoma model (74–76). Based on this preclinical data a phase II clinical trial combining IL-2 with RT was conducted in metastatic melanoma (52).…”

Section: Interleukin 2 (Il-2)mentioning

confidence: 99%

Radiotherapy in Combination With Cytokine Treatment

et al. 2019

View full text Add to dashboard Cite

Radiotherapy (RT) plays an important role in the management of cancer patients. RT is used in more than 50% of patients during the course of their disease in a curative or palliative setting. In the past decades it became apparent that the abscopal effect induced by RT might be dependent on the activation of immune system, and that the induction of immunogenic cancer cell death and production of danger-associated molecular patterns from dying cells play a major role in the radiotherapy-mediated anti-tumor efficacy. Therefore, the combination of RT and immunotherapy is of a particular interest that is reflected in designing clinical trials to treat patients with various malignancies. The use of cytokines as immunoadjuvants in combination with RT has been explored over the last decades as one of the immunotherapeutic combinations to enhance the clinical response to anti-cancer treatment. Here we review mainly the data on the efficacy of IFN-α, IL-2, IL-2-based immunocytokines, GM-CSF, and TNF-α used in combinations with various radiotherapeutic techniques in clinical trials. Moreover, we discuss the potential of IL-15 and its analogs and IL-12 cytokines in combination with RT based on the efficacy in preclinical mouse tumor models.

show abstract

Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2

Cited by 15 publications

References 11 publications

100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series

100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series

Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes

Radiotherapy in Combination With Cytokine Treatment

Contact Info

Product

Resources

About